| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Oncology*
and
Pathology
and the Laboratory of
Medical Genetics,
Helsinki University Central
Hospital, and the Department of Medical
Genetics,
Haartman Institute,
Helsinki, Finland
The genetic changes leading to thyroid cancer are poorly characterized. We studied DNA copy number changes by comparative genomic hybridization (CGH) in 69 primary thyroid carcinomas. In papillary carcinoma, DNA copy number changes were rare (3 of 26, 12%). The changes were all gains, and they were associated with old age (P = 0.01) and the presence of cervical lymph node metastases at presentation (P = 0.08). DNA copy number changes were much more frequent in follicular carcinoma (16 of 20, 80%) than in papillary carcinoma (P < 0.0001), and follicular carcinomas had more often deletions (13/20 versus 0/26, P < 0.0001). Loss of chromosome 22 was common in follicular carcinoma (n = 7, 35%), it was more often seen in widely invasive than in minimally invasive follicular carcinoma (54% versus 0%, P = 0.04), and it was associated with old age at presentation (P = 0.01). In three of the four patients with follicular carcinoma who died of cancer, the tumor had loss of chromosome 22. DNA copy number changes were found in 5 (50%) of the 10 medullary carcinomas studied. Four of these five carcinomas had deletions, and in two of them there was deletion of chromosome 22. Eleven (85%) of the thirteen anaplastic carcinomas investigated had DNA copy number changes, of which five had deletions, and one had deletion of chromosome 22. The most common gains in anaplastic carcinoma were in chromosomes 7p (p22-pter, 31%), 8q (q22-qter, 23%), and 9q (q34-qter, 23%). We conclude that DNA copy number changes are frequent in follicular, medullary, and anaplastic thyroid carcinoma but rare in papillary carcinoma when studied by CGH. Loss of chromosome 22 is particularly common in follicular carcinoma, and it is associated with the widely invasive type.
This article has been cited by other articles:
 |
|
 |
|
  C. Nucera, J. Eeckhoute, S. Finn, J. S. Carroll, A. H. Ligon, C. Priolo, G. Fadda, M. Toner, O. Sheils, M. Attard, et al. FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma Clin. Cancer Res., June 1, 2009; 15(11): 3680 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C Smallridge, L. A Marlow, and J. A Copland Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies Endocr. Relat. Cancer, March 1, 2009; 16(1): 17 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ye, L. Santarpia, G. J. Cote, A. K. El-Naggar, and R. F. Gagel High Resolution Array-Comparative Genomic Hybridization Profiling Reveals Deoxyribonucleic Acid Copy Number Alterations Associated with Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4367 - 4372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Lee, A. Y M Au, T. Foukakis, M. Barbaro, N. Kiss, R. Clifton-Bligh, J. Staaf, A. Borg, L. Delbridge, B. G Robinson, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma Endocr. Relat. Cancer, September 1, 2008; 15(3): 801 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chiappetta, C. De Marco, A. Quintiero, D. Califano, S. Gherardi, D. Malanga, M. Scrima, C. Montero-Conde, L. Cito, M. Monaco, et al. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer Endocr. Relat. Cancer, June 1, 2007; 14(2): 405 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Wreesmann, E. M. Sieczka, N. D. Socci, M. Hezel, T. J. Belbin, G. Childs, S. G. Patel, K. N. Patel, G. Tallini, M. Prystowsky, et al. Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker Cancer Res., June 1, 2004; 64(11): 3780 - 3789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Marsh, G. Theodosopoulos, K. Martin-Schulte, A.-L. Richardson, J. Philips, H.-D. Roher, L. Delbridge, and B. G. Robinson Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1866 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V.-M. Wasenius, S. Hemmer, E. Kettunen, S. Knuutila, K. Franssila, and H. Joensuu Hepatocyte Growth Factor Receptor, Matrix Metalloproteinase-11, Tissue Inhibitor of Metalloproteinase-1, and Fibronectin Are Up-Regulated in Papillary Thyroid Carcinoma: A cDNA and Tissue Microarray Study Clin. Cancer Res., January 1, 2003; 9(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Wreesmann, R. A. Ghossein, S. G. Patel, C. P. Harris, E. A. Schnaser, A. R. Shaha, R. M. Tuttle, J. P. Shah, P. H. Rao, and B. Singh Genome-Wide Appraisal of Thyroid Cancer Progression Am. J. Pathol., November 1, 2002; 161(5): 1549 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Wada, Q.-Y. Duh, D. Miura, L. Brunaud, M. G. Wong, and O. H. Clark Chromosomal Aberrations by Comparative Genomic Hybridization in Hurthle Cell Thyroid Carcinomas Are Associated with Tumor Recurrence J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4595 - 4601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kitamura, K. Shimizu, K. Ito, S. Tanaka, and M. Emi Allelotyping of Follicular Thyroid Carcinoma: Frequent Allelic Losses in Chromosome Arms 7q, 11p, and 22q J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4268 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hemmer, V.-M. Wasenius, C. Haglund, Y. Zhu, S. Knuutila, K. Franssila, and H. Joensuu Deletion of 11q23 and Cyclin D1 Overexpression Are Frequent Aberrations in Parathyroid Adenomas Am. J. Pathol., April 1, 2001; 158(4): 1355 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kitamura, K. Shimizu, S. Tanaka, K. Ito, and M. Emi Association of Allelic Loss on 1q, 4p, 7q, 9p, 9q, and 16q with Postoperative Death in Papillary Thyroid Carcinoma Clin. Cancer Res., May 1, 2000; 6(5): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
